C4 Therapeutics (CCCC) Share-based Compensation: 2019-2025
Historic Share-based Compensation for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to $4.6 million.
- C4 Therapeutics' Share-based Compensation fell 47.99% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.3 million, marking a year-over-year decrease of 16.05%. This contributed to the annual value of $29.7 million for FY2024, which is 8.91% up from last year.
- Latest data reveals that C4 Therapeutics reported Share-based Compensation of $4.6 million as of Q3 2025, which was down 7.99% from $5.0 million recorded in Q2 2025.
- C4 Therapeutics' 5-year Share-based Compensation high stood at $8.9 million for Q1 2022, and its period low was $3.8 million during Q1 2021.
- For the 3-year period, C4 Therapeutics' Share-based Compensation averaged around $6.5 million, with its median value being $6.4 million (2023).
- Its Share-based Compensation has fluctuated over the past 5 years, first soared by 3,214.66% in 2021, then slumped by 47.99% in 2025.
- Quarterly analysis of 5 years shows C4 Therapeutics' Share-based Compensation stood at $6.4 million in 2021, then increased by 8.91% to $6.9 million in 2022, then fell by 8.09% to $6.4 million in 2023, then increased by 29.50% to $8.2 million in 2024, then slumped by 47.99% to $4.6 million in 2025.
- Its Share-based Compensation was $4.6 million in Q3 2025, compared to $5.0 million in Q2 2025 and $5.5 million in Q1 2025.